Sartorius Stedim Biotech SA

DIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|STLOCK|@?>LOCK|DGYJN#

Sartorius Stedim Earnings: Guidance Elevated as Business Remains Resilient; Shares Fairly Valued

Sartorius Stedim Biotech reported third-quarter results, with both sales and adjusted EBITDA beating company-compiled consensus. Sales increased 12% in constant currency, while underlying EBITDA increased 24.6%. The shares traded as much as 12% higher intraday.

Sponsor Center